AstraZeneca Acquires Omniose after two years of collaboration, bringing the Missouri-based biotechnology startup under its ownership to strengthen its infectious disease research. The undervalued acquisition will enable AstraZeneca to have access to the unique bioconjugation technology owned by Omniose that may be able to help with developing conjugate vaccines for treating bacteria-induced diseases, including those caused by antibiotic-resistant bacteria. It will help with the company’s campaign to fight antimicrobial resistance (AMR).

AstraZeneca Brings Omniose’s Vaccine Technology In-House

Under the agreement, Omniose will become a wholly-owned subsidiary of AstraZeneca and a member of its infectious diseases business segment. Even though the details of the transaction have not been revealed, the move is certainly a big step for AstraZeneca’s vaccine development plans.

The agreement comes after a three-year exclusive research collaboration that the firms had initiated in 2024. The firms' collaboration was aimed at developing bioconjugate vaccines against multidrug-resistant bacteria, often referred to as superbugs.

The CEO of the infectious diseases unit of AstraZeneca, Benjamin Moutier, referred to Omniose’s technology as an innovative means of conjugate vaccine design. He emphasized its ability to help design vaccines that protect from the deadliest bacterial infections.

Omniose Platform Could Simplify Conjugate Vaccine Production

The central attraction of the AstraZeneca Omniose acquisition is the startup’s bioconjugation platform. The technology allows the bacteria to produce bacterial polysaccharides and carrier proteins, the two important ingredients for conjugate vaccines, in one bacteria cell.

Whereas the conventional vaccine production process through chemistry may be quite difficult and complex, making vaccine development difficult to scale, the Omniose vaccine production technique is simpler and easier.

This is a very flexible technology as it is adaptable for virtually any polysaccharide derived from bacteria and can therefore increase the number of bacterial diseases researchers can target using conjugated vaccines.

Omniose has carried out studies on Klebsiella pneumonia, which is a bacterium that causes pneumonia and UTIs, as well as other bacteria that belong to the Moraxellaceae family. The company has also found positive preclinical data on mice in terms of an invasive pneumococcal disease vaccine.

Rising Antimicrobial Resistance Strengthens Vaccine Demand

This acquisition is made in light of the fact that there is an increased occurrence of antimicrobial resistance, which has become a global health challenge. There are some bacteria, including MRSA, drug-resistant Streptococcus pneumonia and Mycobacterium tuberculosis, among others.

According to World Health Organization, antimicrobial resistance in bacteria led to approximately 4.7 million deaths across the world in 2021. By 2023, about one in every six laboratory-identified bacterial infections was resistant to antibiotic medication.

The WHO attributes the following as some of the reasons behind the problem: antimicrobial misuse, overuse, vaccine and diagnostic access limitations.

This acquisition will help AstraZeneca boost its research abilities and look into some preventive options that can be used for treating bacterial infections that are hard to cure. The exact vaccine targets have not been disclosed yet, but this technology from Omniose might prove valuable in the future.

Thus, Business Fortune believes that AstraZeneca’s acquisition of Omniose could accelerate vaccine innovation and strengthen global efforts to combat growing antimicrobial resistance.

Sources: Business Wire, Pharmaceutical Technology,

FAQs

Why did AstraZeneca acquire Omniose?

AstraZeneca acquired Omniose to gain access to its bioconjugation platform and strengthen its development of vaccines against serious bacterial infections.

What is Omniose's bioconjugation platform?

It is a technology that produces and combines bacterial polysaccharides with engineered carrier proteins inside a single bacterial cell.

How much did AstraZeneca pay for Omniose?

The financial details of the acquisition have not been publicly disclosed.

What was the previous partnership between AstraZeneca and Omniose?

The companies began a three-year exclusive research collaboration in 2024, focusing on bioconjugate vaccines against multidrug-resistant bacteria.

How could the acquisition help fight antimicrobial resistance?

It could support the development of new preventive vaccines against drug-resistant bacteria, potentially reducing infections and dependence on antibiotics.